Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole

Neuropsychopharmacology

Volumn 35, Issue 3, 2010, Pages 834-846

  Brennan, Brian P ^a,b   Hudson, James I ^a,b   Jensen, J Eric ^a,b   McCarthy, Julie ^a   Roberts, Jacqueline L ^a   Prescot, Andrew P ^c   Cohen, Bruce M ^a,b   Pope, Harrison G ^a,b   Renshaw, Perry F ^c   Ngür, Dost ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c The Brain Institute at the University of Utah   (United States)

Author keywords

Bipolar disorder; Depression; Glutamate; MRS; N acetylaspartate; Riluzole

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; CLONAZEPAM; DIAZEPAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; GLUTAMIC ACID; GLUTAMINE; LORAZEPAM; N ACETYLASPARTIC ACID; QUETIAPINE; RILUZOLE; TRAZODONE; VENLAFAXINE; ZIPRASIDONE; ZOLPIDEM;

ADULT; AGED; ARTICLE; BIPOLAR DEPRESSION; CINGULATE GYRUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HAMILTON SCALE; HUMAN; MALE; NERVE CELL PLASTICITY; NEUROIMAGING; NEUROTRANSMISSION; OCCIPITAL CORTEX; PARIETAL LOBE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TREATMENT OUTCOME;

ADULT; BIPOLAR DISORDER; FEMALE; GLUTAMIC ACID; GYRUS CINGULI; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RILUZOLE; SYNAPTIC TRANSMISSION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 75749131012     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.191     Document Type: Article

References (64)

1. Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL et al (2008). Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry (e-pub ahead of print 30 September).
2. Batra NA, Seres-Mailo J, Hanstock C, Seres P, Khudabux J, Bellavance F et al (2008). Proton magnetic resonance spectro-scopy measurement of brain glutamate levels in premenstrual dysphoric disorder. Biol Psychiatry 63: 1178-1184.
3. Bhagwagar Z, Wylezinska M, Jezzard P, Evans J, Ashworth F, Sule A et al (2007). Reduction in occipital cortex gamma-aminobu-tyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biol Psychiatry 61: 806-812.
4. Cecil KM, DelBello MP, Morey R, Strakowski SM (2002). Frontal lobe differences in bipolar disorder as determined by proton MR spectroscopy. Bipolar Disord 4: 357-365.
5. Cheramy A, Barbeito L, Godeheu G, Glowinski J (1992). Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 147: 209-212.
6. Choi IY, Gruetter R (2004). Dynamic or inert metabolism? Turnover of N-acetyl aspartate and glutathione from D-[1-13C]glucose in the rat brain in vivo. J Neurochem 91: 778-787.
7. Chowdhury GM, Banasr M, de Graaf RA, Rothman DL, Behar KL, Sanacora G (2008). Chronic riluzole treatment increases glucose metabolism in rat prefrontal cortex and hippocampus. J Cereb Blood Flow Metab 28: 1892-1897.
8. Cohen J (1977). Statistical Power Analysis for the Behavioral Sciences, revised edition. Academic Press: New York.
9. Dager SR, Friedman SD, Parow A, Demopulos C, Stoll AL, Lyoo IK et al (2004). Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry 61: 450-458.
10. Diggle PJ, Liang KY, Zeger SL (1994). Analysis of Longitudinal Data. Oxford University Press: Oxford, England.
11. Doble A (1996). The pharmacology and mechanism of action of riluzole. Neurology 47(6 Suppl 4): S233-S241.
12. Doble A, Hubert JP, Blanchard JC (1992). Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on D-[3H]aspartate release from cultured cerebellar granule cells. Neurosci Lett 140: 251-254.
13. Du J, Suzuki K, Wei Y, Wang Y, Blumenthal R, Chen Z et al (2007). The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuro-psychopharmacology 32: 793-802.
14. Fitzmaurice GM, Laird NM, Ware JH (2004). Applied Longitudinal Analysis. John Wiley & Sons: Hoboken, New Jersey.
15. Frye MA, Watzl J, Banakar S, O'Neill J, Mintz J, Davanzo P et al (2007). Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. Neuropsychophar-macology 32: 2490-2499.
16. Fumagalli E, Funicello M, Rauen T, Gobbi M, Mennini T (2008). Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur J Pharmacol 578: 171-176.
17. Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB et al (1993). Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry 50: 739-750.
18. Hardingham GE (2006). Pro-survival signalling from the NMDA receptor. Biochem Soc Trans 34(Pt 5): 936-938.
19. Hirashima F, Parow AM, Stoll AL, Demopulos CM, Damico KE, Rohan ML et al (2004). Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. Am J Psychiatry 161: 1922-1924.
20. Igarashi H, Kwee IL, Nakada T, Katayama Y, Terashi A (2001). 1H magnetic resonance spectroscopic imaging of permanent focal cerebral ischemia in rat: longitudinal metabolic changes in ischemic core and rim. Brain Res 907: 208-221.
21. Iltis I, Koski DM, Eberly LE, Nelson CD, Deelchand DK, Valette J et al (2009). Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized (1)H MRS study. NMR Biomed 22: 737-744.
22. Jensen JE, Licata SC, Öngür D, Friedman SD, Prescot AP, Henry ME et al (2009). Quantification of J-resolved proton spectra in two-dimensions with LCModel using GAMMA-simulated basis sets at 4 Tesla. NMR Biomed 22: 762-769.
23. Kalra S, Cashman NR, Genge A, Arnold DL (1998). Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 9: 1757-1761.
24. Kalra S, Tai P, Genge A, Arnold DL (2006). Rapid improvement in cortical neuronal integrity in amyotrophic lateral sclerosis detected by proton magnetic resonance spectroscopic imaging. J Neurol 253: 1060-1063.
25. Kugaya A, Sanacora G (2005). Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr 10: 808-819.
26. Lauterborn JC, Lynch G, Vanderklish P, Arai A, Gall CM (2000). Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci 20: 8-21.
27. Lauterborn JC, Pineda E, Chen LY, Ramirez EA, Lynch G, Gall CM (2009). Ampakines cause sustained increases in brain-derived neurotrophic factor signaling at excitatory synapses without changes in AMPA receptor subunit expression. Neuroscience 159: 283-295.
28. Mackowiak M, O'Neill MJ, Hicks CA, Bleakman D, Skolnick P (2002). An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study. Neuropharmacology 43: 1-10.
29. Maeng S, Zarate Jr CA, Du J, Schloesser RJ, McCammon J, Chen G et al (2008). Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63: 349-352.
30. Martin D, Thompson MA, Nadler JV (1993). The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 250: 473-476.
31. Mathew SJ, Price RB, Mao X, Smith EL, Coplan JD, Charney DS et al (2008). Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol Psychiatry 63: 891-898.
32. Michael N, Erfurth A, Ohrmann P, Gossling M, Arolt V, Heindel W et al (2003). Acute mania is accompanied by elevated glutamate/ glutamine levels within the left dorsolateral prefrontal cortex. Psychopharmacology (Berl) 168: 344-346.
33. Michael N, Erfurth A, Pfleiderer B (2009). Elevated metabolites within dorsolateral prefrontal cortex in rapid cycling bipolar disorder. Psychiatry Res 172: 78-81.
34. Mlynarik V, Kohler I, Gambarota G, Vaslin A, Clarke PG, Gruetter R (2008). Quantitative proton spectroscopic imaging of the neurochemical profile in rat brain with microliter resolution at ultra-short echo times. Magn Reson Med 59: 52-58.
35. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM (2007). N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 81: 89-131.
36. Mu X, Azbill RD, Springer JE (2000). Riluzole improves measures of oxidative stress following traumatic spinal cord injury. Brain Res 870: 66-72.
37. Öngür D, Jensen JE, Prescot AP, Stork C, Lundy M, Cohen BM et al (2008). Abnormal glutamatergic neurotransmission and neuro-nal-glial interactions in acute mania. Biol Psychiatry 64: 718-726.
38. Ongür D, Prescot AP, Jensen JE, Cohen BM, Renshaw PF (2009a). Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res 172: 44-48.
39. Öngür D, Prescot AP, Jensen JE, Rouse ED, Cohen BM, Renshaw PF et al (2009b). T2 relaxation time abnormalities in bipolar disorder and schizophrenia. Magn Reson Med (in press).
40. Oz G, Terpstra M, Tkac I, Aia P, Lowary J, Tuite PJ et al (2006). Proton MRS of the unilateral substantia nigra in the human brain at 4 Tesla: detection of high GABA concentrations. Magn Reson Med 55: 296-301.
41. Phillips ML, Drevets WC, Rauch SL, Lane R (2003). Neurobiology of emotion perception II: implications for major psychiatric disorders. Biol Psychiatry 54: 515-528.
42. Post RM (2005). The impact of bipolar depression. J Clin Psychiatry 66(Suppl 5): 5-10.
43. Prakriya M, Mennerick S (2000). Selective depression of low-release probability excitatory synapses by sodium channel blockers. Neuron 26: 671-682.
44. Provencher SW (1993). Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30: 672-679.
45. Rothman DL, Behar KL, Hyder F, Shulman RG (2003). In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function. Annu Rev Physiol 65: 401-427.
46. Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E et al (2005). Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 162: 394-396.
47. Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL et al (2004). Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 61: 705-713.
48. Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V et al (2007). Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 61: 822-825.
49. Sanacora G, Rothman DL, Mason G, Krystal JH (2003). Clinical studies implementing glutamate neurotransmission in mood disorders. Ann N Y Acad Sci 1003: 292-308.
50. Sanacora G, Zarate CA, Krystal JH, Manji HK (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7: 426-437.
51. Schloesser RJ, Huang J, Klein PS, Manji HK (2008). Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 33: 110-133.
52. Schulte RF, Boesiger P (2006a). ProFit: two-dimensional prior-knowledge fitting of J-resolved spectra. NMR Biomed 19: 255-263.
53. Schulte RF, Lange T, Beck J, Meier D, Boesiger P (2006b). Improved two-dimensional J-resolved spectroscopy. NMR Biomed 19: 264-270.
54. Theberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, Rajakumar N et al (2003). Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 160: 2231-2233.
55. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J et al (2002). Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 159: 1944-1946.
56. Valentine GW, Sanacora G (2009). Targeting glial physiology and glutamate cycling in the treatment of depression. Biochem Pharmacol (e-pub ahead of print 17 April).
57. Voss OP, Milne S, Sharkey J, O'Neill MJ, McCulloch J (2007). Molecular mechanisms of neurite growth with AMPA receptor potentiation. Neuropharmacology 52: 590-597.
58. Wang SJ, Wang KY, Wang WC (2004). Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience 125: 191-201.
59. Wu X, Zhu D, Jiang X, Okagaki P, Mearow K, Zhu G et al (2004). AMPA protects cultured neurons against glutamate excitotoxi-city through a phosphatidylinositol 3-kinase-dependent activation in extracellular signal-regulated kinase to upregulate BDNF gene expression. J Neurochem 90: 807-818.
60. Zarate Jr CA, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D et al (2004). An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 161: 171-174.
61. Zarate Jr CA, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA et al (2005). An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 57: 430-432.
62. Zarate Jr CA, Singh J, Manji HK (2006a). Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 59: 1006-1020.
63. Zarate Jr CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al (2006b). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-864.
64. Zhang QG, Han D, Hu SQ, Li C, Yu CZ, Wang R et al (2009). Positive modulation of AMPA receptors prevents down-regulation of GluR2 expression and activates the Lyn-ERK1/2-CREB signaling in rat brain ischemia. Hippocampus (e-pub ahead of print 27 March 2009).